Combined use of crystalline sodium salt and polymeric precipitation inhibitors to improve pharmacokinetic profile of ibuprofen through supersaturation

AAPS PharmSciTech

Volumn 15, Issue 5, 2014, Pages 1334-1344

  Terebetski, Jenna L ^a,b   Cummings, John J ^b   Fauty, Scott E ^b   Michniak Kohn, Bozena ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

dissolution; ibuprofen; pharmacokinetic profile; precipitation inhibitor; supersaturation

Indexed keywords

CRYSTALLINE SODIUM SALT; HYDROXYPROPYLCELLULOSE; IBUPROFEN; METHYLCELLULOSE; POLYVINYL ACETATE; POVIDONE; SODIUM DERIVATIVE; UNCLASSIFIED DRUG; EXCIPIENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMER; SODIUM;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SOLUBILITY; DRUG SUPERSATURATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; MEDICINAL CHEMISTRY; SOLUBILITY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; IBUPROFEN; MALE; POLYMERS; RATS; RATS, WISTAR; SODIUM; SOLUBILITY;

EID: 84907874333     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0163-2     Document Type: Article

References (31)

1. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci. 1977;66(1):1-19.
2. Stahl P, Wermuth C. Handbook of pharmaceutical salts: properties, selection, and use. 2nd revised ed. New York: Wiley-VCH; 2011
3. Serajuddin A. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603-16.
4. Warren DB, Benameur H, Porter CJH, Pouton CW. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Targeting. 2010;00:1-28.
5. Xu S, Dai W-G. Drug precipitation inhibitors in supersaturable formulations. Int J Pharm. 2013;453:36-43.
6. Gao P, Shi Y. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J. 2012;14(4):703-13.
7. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96(10):2686-702.
8. Rowe R, Sheskey P, Cook W, Fenton M. Handbook of pharmaceutical excipients. 7th ed. London, UK: Pharmaceutical Press; 2012.
9. Ridell A, Evertsson H, Nilsson S, Sundelöf LO. Amphiphilic association of ibuprofen and two nonionic cellulose derivatives in aqueous solution. J Pharm Sci. 1999;88(11):1175-81.
10. Rainsford K. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17(6):275-342.
11. Rainsford KD. Ibuprofen: pharmacology, therapeutics and side effects: pharmacology, therapeutics and side effects. Basel & Heidelberg: Springer; 2012.
12. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121-31.
13. Bevernage J, Brouwers J, Brewster ME, Augustijns P. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 2013;453(1):25-35.
14. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility limited oral bioavailability? J Pharm Sci. 2009;98(8):2549-72.
15. Kashchiev D, Van Rosmalen GM. Review: nucleation in solutions revisited. Cryst Res Technol. 2003;38(7-8):555-74.
16. Rodríguez-Hornedo N, Murphy D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci. 1999;88(7):651-60.
17. Ozaki S, Minamisono T, Yamashita T, Kato T, Kushida I. Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. J Pharm Sci. 2012;101(1):214-22.
18. Patel DD, Anderson BD. Maintenance of supersaturation ii: Indomethacin crystal growth kinetics versus degree of supersaturation. J Pharm Sci. 2013;102(5):1544-53.
19. Jia Z, Choi DS, Chokshi H. Determination of drug-polymer binding constants by affinity capillary electrophoresis for aryl propionic acid derivatives and related compounds. J Pharm Sci. 2013;102(3):960-6.
20. Raghavan S, Trividic A, Davis A, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 2001;212(2):213-21.
21. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409(1):260-8.
22. Hardung H, Djuric D, Ali S. Combining HME & solubilization: Soluplus® the solid solution. Drug Deliv Tech. 2010;10(3):20-7.
23. Tiwari SB, Rajabi-Siahboomi AR. Extended release oral drug delivery technologies: monolithic matrix systems. Chapter 11. In: Jain K, editor. Methods in molecular biology: drug delivery systems, vol. 437. USA: Humana Press; 2008. p. 217-43.
24. Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011;154(1):2-19.
25. Newa M, Bhandari KH, Lee DX, Sung JH, Kim JA, Yoo BK, et al. Enhanced dissolution of ibuprofen using solid dispersion with polyethylene glycol 20000. Drug Dev Ind Pharm. 2008;34(10):1013-21.
26. Haruta S, Kawai K, Jinnouchi S, Ogawara K, Higaki K, Tamura S, et al. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy. J Pharm Sci. 2001;90(4):464-73.
27. Scarpignato C, Girone MG, Tirelli F, Bertaccini G. Inhibition of gastric emptying and secretion by pirenzepine and atropine in rats. Eur J Pharm Sci. 1984;101(3):193-200.
28. Gao Y, Carr RA, Spence JK, Wang WW, Turner TM, Lipari JM, et al. A ph-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling. Mol Pharm. 2010;7(5):1516-26.
29. DiNunzio JC, Hughey JR, Brough C, Miller DA, Williams III RO, McGinity JW. Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol® dispersing. Drug Dev Ind Pharm. 2010;36(9):1064-78.
30. Miller MA, DiNunzio J, Matteucci ME, Ludher BS, Williams RO, Johnston KP. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm. 2012;38(5):557-70.
31. Ranzani LS, Font J, Galimany F, Santanach A, Gomez-Gomar AM, Casadevall G, et al. Enhanced in vivo absorption of CB-1 antagonist in rats via solid solutions prepared by hot-melt extrusion. Drug Dev Ind Pharm. 2011;37(6):694-701.